Follow the people · Insider
Robert Hershberg
Robert Hershberg files insider transactions with the SEC as a director of Adaptive Biotechnologies (ADPT). We hold 2 disclosed purchases and sales filed since 23 January 2006, 2 of them in the last 90 days.
- Files forADPT
- Disclosed buys and sells2 in all, 2 in the last 90 days
- Last disclosure20 August 2026
Positions held
8 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 13 February 2020 — 18 August 2026Director · Adaptive Biotechnologies (ADPT)68 Form 4 lines · source: SEC Form 4
- Filed 5 November 2025 — 7 July 2026Director · AtaiBeckley (ATAI)10 Form 4 lines · source: SEC Form 4
- Filed 15 April 2021 — 17 June 2026Director · Recursion Pharmaceuticals (RXRX)20 Form 4 lines · source: SEC Form 4
- Filed 1 February 2023 — 17 September 2025President and CEO · HilleVax (HLVX)8 Form 4 lines · source: SEC Form 4
- Filed 1 May 2020 — 6 June 2023Director · Fate Therapeutics (FATE)8 Form 4 lines · source: SEC Form 4
- Filed 3 December 2020 — 10 June 2022Director · Silverback Therapeutics (SBTX)3 Form 4 lines · source: SEC Form 4
- Filed 2 March 2015 — 18 April 2022Director · NanoString Technologies (NSTG)71 Form 4 lines · source: SEC Form 4
- Filed 31 January 2005 — 19 January 2006Sr. VP & Chief Medical Officer · Dendreon (DNDN)2 Form 4 lines · source: SEC Form 4
Everything they disclosed
120 entries, newest first — one per disclosure report, one per Form 4 line- exercised options over 15,000 shares of Adaptive BiotechnologiesSEC Form 420 August 2026Common Stock · traded 18 August 2026 · filed 20 August 2026
- ▼ sold on the open market 15,000 shares of Adaptive BiotechnologiesSEC Form 420 August 2026Common Stock · traded 18 August 2026 · filed 20 August 2026
- ▼ sold on the open market 15,664 shares of Adaptive BiotechnologiesSEC Form 420 August 2026Common Stock · traded 18 August 2026 · filed 20 August 2026
- exercised options over 15,000 shares of Adaptive Biotechnologies (a derivative holding)SEC Form 420 August 2026Stock Option (right to buy) · traded 18 August 2026 · filed 20 August 2026
- exercised options over 48,858 shares of AtaiBeckleySEC Form 49 July 2026Common Stock · traded 7 July 2026 · filed 9 July 2026
- exercised options over 51,142 shares of AtaiBeckleySEC Form 49 July 2026Common Stock · traded 7 July 2026 · filed 9 July 2026
- ▼ sold on the open market 100,000 shares of AtaiBeckleySEC Form 49 July 2026Common Stock · traded 7 July 2026 · filed 9 July 2026
- exercised options over 48,858 shares of AtaiBeckley (a derivative holding)SEC Form 49 July 2026Stock Option · traded 7 July 2026 · filed 9 July 2026
- exercised options over 51,142 shares of AtaiBeckley (a derivative holding)SEC Form 49 July 2026Stock Option · traded 7 July 2026 · filed 9 July 2026
- was granted 88,424 shares of Recursion PharmaceuticalsSEC Form 422 June 2026Class A Common Stock · traded 17 June 2026 · filed 22 June 2026
- was granted 121,968 shares of AtaiBeckley (a derivative holding)SEC Form 48 June 2026Stock Option · traded 4 June 2026 · filed 8 June 2026
- was granted 15,625 shares of Adaptive BiotechnologiesSEC Form 46 March 2026Common Stock · traded 4 March 2026 · filed 6 March 2026
- was granted 15,625 shares of Adaptive BiotechnologiesSEC Form 46 March 2026Common Stock · traded 4 March 2026 · filed 6 March 2026
- ▼ sold on the open market 22,968 shares of Adaptive BiotechnologiesSEC Form 412 December 2025Common Stock · traded 10 December 2025 · filed 12 December 2025
- was granted 456,011 shares of Atai Beckley (a derivative holding)SEC Form 46 November 2025Stock Option · traded 5 November 2025 · filed 6 November 2025
- was granted 97,716 shares of Atai Beckley (a derivative holding)SEC Form 46 November 2025Stock Option · traded 5 November 2025 · filed 6 November 2025
- was granted 62,394 shares of Atai Beckley (a derivative holding)SEC Form 46 November 2025Stock Option · traded 5 November 2025 · filed 6 November 2025
- was granted 103,000 shares of Atai Beckley (a derivative holding)SEC Form 46 November 2025Stock Option · traded 5 November 2025 · filed 6 November 2025
- disposed of in a tender offer 1,101,498 shares of HilleVaxSEC Form 417 September 2025Common Stock · traded 17 September 2025 · filed 17 September 2025
- was granted 44,031 shares of Recursion Pharmaceuticals (a derivative holding)SEC Form 423 June 2025Stock Option (Right to Buy) · traded 18 June 2025 · filed 23 June 2025
- was granted 22,016 shares of Recursion PharmaceuticalsSEC Form 423 June 2025Class A Common Stock · traded 18 June 2025 · filed 23 June 2025
- ▼ sold on the open market 53,000 shares of Adaptive BiotechnologiesSEC Form 412 March 2025Common Stock · traded 12 March 2025 · filed 12 March 2025
- was granted 23,726 shares of Adaptive Biotechnologies (a derivative holding)SEC Form 46 March 2025Stock Option (right to buy) · traded 4 March 2025 · filed 6 March 2025
- was granted 15,394 shares of Adaptive BiotechnologiesSEC Form 46 March 2025Common Stock · traded 4 March 2025 · filed 6 March 2025
- ▼ sold on the open market 14,634 shares of HilleVaxSEC Form 412 February 2025Common Stock · traded 4 February 2025 · filed 12 February 2025
- ▼ sold on the open market 11,901 shares of HilleVaxSEC Form 412 February 2025Common Stock · traded 11 February 2025 · filed 12 February 2025
- was granted 26,193 shares of Recursion Pharmaceuticals (a derivative holding)SEC Form 45 June 2024Stock Option (Right to Buy) · traded 3 June 2024 · filed 5 June 2024
- was granted 13,097 shares of Recursion PharmaceuticalsSEC Form 45 June 2024Class A Common Stock · traded 3 June 2024 · filed 5 June 2024
- was granted 48,044 shares of Adaptive Biotechnologies (a derivative holding)SEC Form 46 March 2024Stock Option (right to buy) · traded 4 March 2024 · filed 6 March 2024
- was granted 31,328 shares of Adaptive BiotechnologiesSEC Form 46 March 2024Common Stock · traded 4 March 2024 · filed 6 March 2024
- was granted 226,885 shares of HilleVax (a derivative holding)SEC Form 412 February 2024Stock Option (Right to Buy) · traded 8 February 2024 · filed 12 February 2024
- ▼ sold on the open market 11,597 shares of HilleVaxSEC Form 412 February 2024Common Stock · traded 8 February 2024 · filed 12 February 2024
- was granted 174,202 shares of HilleVaxSEC Form 412 February 2024Common Stock · traded 8 February 2024 · filed 12 February 2024
- was granted 25,224 shares of Recursion Pharmaceuticals (a derivative holding)SEC Form 421 June 2023Stock Option (Right to Buy) · traded 16 June 2023 · filed 21 June 2023
- was granted 12,612 shares of Recursion PharmaceuticalsSEC Form 421 June 2023Class A Common Stock · traded 16 June 2023 · filed 21 June 2023
- was granted 40,000 shares of Fate Therapeutics (a derivative holding)SEC Form 47 June 2023Stock Option (Right to Buy) · traded 6 June 2023 · filed 7 June 2023
- was granted 23,329 shares of Adaptive Biotechnologies (a derivative holding)SEC Form 48 March 2023Stock Option (right to buy) · traded 6 March 2023 · filed 8 March 2023
- was granted 14,775 shares of Adaptive BiotechnologiesSEC Form 48 March 2023Common Stock · traded 6 March 2023 · filed 8 March 2023
- was granted 381,950 shares of HilleVax (a derivative holding)SEC Form 43 February 2023Stock Option (Right to Buy) · traded 1 February 2023 · filed 3 February 2023
- was granted 187,966 shares of HilleVaxSEC Form 43 February 2023Common Stock · traded 1 February 2023 · filed 3 February 2023
- exercised options over 53,000 shares of Adaptive Biotechnologies (a derivative holding)SEC Form 43 February 2023Stock Option (Right to Buy) · traded 2 February 2023 · filed 3 February 2023
- exercised options over 53,000 shares of Adaptive BiotechnologiesSEC Form 43 February 2023Common Stock · traded 2 February 2023 · filed 3 February 2023
- was granted 36,290 shares of Recursion Pharmaceuticals (a derivative holding)SEC Form 416 June 2022Stock Option (right to buy) · traded 14 June 2022 · filed 16 June 2022
- was granted 18,145 shares of Recursion PharmaceuticalsSEC Form 416 June 2022Class A Common Stock · traded 14 June 2022 · filed 16 June 2022
- was granted 11,893 shares of Fate Therapeutics (a derivative holding)SEC Form 413 June 2022Stock Option (Right to Buy) · traded 9 June 2022 · filed 13 June 2022
- was granted 8,650 shares of Fate TherapeuticsSEC Form 413 June 2022Common Stock · traded 9 June 2022 · filed 13 June 2022
- was granted 18,000 shares of Silverback Therapeutics (a derivative holding)SEC Form 413 June 2022Stock Option (right to buy) · traded 10 June 2022 · filed 13 June 2022
- ▼ sold on the open market 672 shares of Fate TherapeuticsSEC Form 46 June 2022Common Stock · traded 3 June 2022 · filed 6 June 2022
- exercised options over 3,306 shares of NanoString Technologies (a derivative holding)SEC Form 418 April 2022Common Stock · traded 18 April 2022 · filed 18 April 2022
- exercised options over 3,306 shares of NanoString TechnologiesSEC Form 418 April 2022Common Stock · traded 18 April 2022 · filed 18 April 2022
- was granted 16,722 shares of Adaptive Biotechnologies (a derivative holding)SEC Form 428 January 2022Stock Option (Right to Buy) · traded 26 January 2022 · filed 28 January 2022
- was granted 6,689 shares of Adaptive BiotechnologiesSEC Form 428 January 2022Common Stock · traded 26 January 2022 · filed 28 January 2022
- was granted 693 shares of Recursion PharmaceuticalsSEC Form 45 January 2022Class A Common Stock · traded 3 January 2022 · filed 5 January 2022
- was granted 572 shares of Recursion PharmaceuticalsSEC Form 45 October 2021Class A Common Stock · traded 1 October 2021 · filed 5 October 2021
- was granted 15,000 shares of Silverback Therapeutics (a derivative holding)SEC Form 421 September 2021Stock Option (right to buy) · traded 4 June 2021 · filed 21 September 2021
- was granted 347 shares of Recursion PharmaceuticalsSEC Form 46 July 2021Class A Common Stock · traded 1 July 2021 · filed 6 July 2021
- exercised options over 5,520 shares of NanoString TechnologiesSEC Form 417 June 2021Common Stock · traded 15 June 2021 · filed 17 June 2021
- exercised options over 5,520 shares of NanoString Technologies (a derivative holding)SEC Form 417 June 2021Common Stock · traded 15 June 2021 · filed 17 June 2021
- was granted 3,890 shares of NanoString Technologies (a derivative holding)SEC Form 417 June 2021Common Stock · traded 16 June 2021 · filed 17 June 2021
- was granted 2,681 shares of Fate TherapeuticsSEC Form 44 June 2021Common Stock · traded 2 June 2021 · filed 4 June 2021
- was granted 4,334 shares of Fate Therapeutics (a derivative holding)SEC Form 44 June 2021Stock Option (Right to Buy) · traded 2 June 2021 · filed 4 June 2021
- converted 6,250 shares of Recursion PharmaceuticalsSEC Form 422 April 2021Common Stock · traded 20 April 2021 · filed 22 April 2021
- converted 6,250 shares of Recursion PharmaceuticalsSEC Form 422 April 2021Class A Common Stock · traded 20 April 2021 · filed 22 April 2021
- converted 12,500 shares of Recursion Pharmaceuticals (a derivative holding)SEC Form 422 April 2021Stock Option (Right to Buy) · traded 20 April 2021 · filed 22 April 2021
- converted 12,500 shares of Recursion Pharmaceuticals (a derivative holding)SEC Form 422 April 2021Stock Option (Right to Buy) · traded 20 April 2021 · filed 22 April 2021
- converted 525,000 shares of Recursion Pharmaceuticals (a derivative holding)SEC Form 422 April 2021Stock Option (Right to Buy) · traded 20 April 2021 · filed 22 April 2021
- converted 525,000 shares of Recursion Pharmaceuticals (a derivative holding)SEC Form 422 April 2021Stock Option (Right to Buy) · traded 20 April 2021 · filed 22 April 2021
- was granted 6,250 shares of Recursion PharmaceuticalsSEC Form 419 April 2021Common Stock · traded 16 April 2021 · filed 19 April 2021
- was granted 12,500 shares of Recursion Pharmaceuticals (a derivative holding)SEC Form 419 April 2021Stock Option (Right to Buy) · traded 15 April 2021 · filed 19 April 2021
- exercised options over 144 shares of NanoString Technologies (a derivative holding)SEC Form 419 April 2021Stock Option (right to buy) · traded 15 April 2021 · filed 19 April 2021
- exercised options over 144 shares of NanoString TechnologiesSEC Form 419 April 2021Common Stock · traded 15 April 2021 · filed 19 April 2021
- ▼ sold on the open market 7 shares of NanoString TechnologiesSEC Form 419 April 2021Common Stock · traded 15 April 2021 · filed 19 April 2021
- ▼ sold on the open market 19 shares of NanoString TechnologiesSEC Form 419 April 2021Common Stock · traded 15 April 2021 · filed 19 April 2021
- ▼ sold on the open market 118 shares of NanoString TechnologiesSEC Form 419 April 2021Common Stock · traded 15 April 2021 · filed 19 April 2021
- exercised options over 1,500 shares of NanoString TechnologiesSEC Form 417 March 2021Common Stock · traded 15 March 2021 · filed 17 March 2021
- ▼ sold on the open market 4 shares of NanoString TechnologiesSEC Form 417 March 2021Common Stock · traded 15 March 2021 · filed 17 March 2021
- ▼ sold on the open market 282 shares of NanoString TechnologiesSEC Form 417 March 2021Common Stock · traded 15 March 2021 · filed 17 March 2021
- ▼ sold on the open market 1,214 shares of NanoString TechnologiesSEC Form 417 March 2021Common Stock · traded 15 March 2021 · filed 17 March 2021
- exercised options over 1,500 shares of NanoString Technologies (a derivative holding)SEC Form 417 March 2021Stock Option (right to buy) · traded 15 March 2021 · filed 17 March 2021
- exercised options over 2,000 shares of Adaptive BiotechnologiesSEC Form 410 March 2021Common Stock · traded 8 March 2021 · filed 10 March 2021
- ▼ sold on the open market 2,000 shares of Adaptive BiotechnologiesSEC Form 410 March 2021Common Stock · traded 8 March 2021 · filed 10 March 2021
- exercised options over 2,000 shares of Adaptive Biotechnologies (a derivative holding)SEC Form 410 March 2021Stock Option (Right to Buy) · traded 8 March 2021 · filed 10 March 2021
- exercised options over 2,000 shares of Adaptive Biotechnologies (a derivative holding)SEC Form 410 March 2021Stock Option (Right to Buy) · traded 8 March 2021 · filed 10 March 2021
- exercised options over 2,000 shares of Adaptive BiotechnologiesSEC Form 410 March 2021Common Stock · traded 8 March 2021 · filed 10 March 2021
- ▼ sold on the open market 2,000 shares of Adaptive BiotechnologiesSEC Form 410 March 2021Common Stock · traded 8 March 2021 · filed 10 March 2021
- exercised options over 1,188 shares of NanoString TechnologiesSEC Form 418 February 2021Common Stock · traded 16 February 2021 · filed 18 February 2021
- ▼ sold on the open market 318 shares of NanoString TechnologiesSEC Form 418 February 2021Common Stock · traded 16 February 2021 · filed 18 February 2021
- ▼ sold on the open market 323 shares of NanoString TechnologiesSEC Form 418 February 2021Common Stock · traded 16 February 2021 · filed 18 February 2021
- ▼ sold on the open market 159 shares of NanoString TechnologiesSEC Form 418 February 2021Common Stock · traded 16 February 2021 · filed 18 February 2021
- ▼ sold on the open market 156 shares of NanoString TechnologiesSEC Form 418 February 2021Common Stock · traded 16 February 2021 · filed 18 February 2021
- ▼ sold on the open market 163 shares of NanoString TechnologiesSEC Form 418 February 2021Common Stock · traded 16 February 2021 · filed 18 February 2021
- ▼ sold on the open market 69 shares of NanoString TechnologiesSEC Form 418 February 2021Common Stock · traded 16 February 2021 · filed 18 February 2021
- exercised options over 1,188 shares of NanoString Technologies (a derivative holding)SEC Form 418 February 2021Stock Option (right to buy) · traded 16 February 2021 · filed 18 February 2021
- was granted 1,504 shares of Adaptive BiotechnologiesSEC Form 417 February 2021Common Stock · traded 14 February 2021 · filed 17 February 2021
- exercised options over 2,000 shares of Adaptive BiotechnologiesSEC Form 417 February 2021Common Stock · traded 16 February 2021 · filed 17 February 2021
- ▼ sold on the open market 2,000 shares of Adaptive BiotechnologiesSEC Form 417 February 2021Common Stock · traded 16 February 2021 · filed 17 February 2021
- was granted 3,759 shares of Adaptive Biotechnologies (a derivative holding)SEC Form 417 February 2021Stock Option (Right to Buy) · traded 14 February 2021 · filed 17 February 2021
- exercised options over 2,000 shares of Adaptive Biotechnologies (a derivative holding)SEC Form 417 February 2021Stock Option (Right to Buy) · traded 16 February 2021 · filed 17 February 2021
- exercised options over 2,000 shares of Adaptive BiotechnologiesSEC Form 420 January 2021Common Stock · traded 15 January 2021 · filed 20 January 2021
- ▼ sold on the open market 1,378 shares of Adaptive BiotechnologiesSEC Form 420 January 2021Common Stock · traded 15 January 2021 · filed 20 January 2021
- ▼ sold on the open market 622 shares of Adaptive BiotechnologiesSEC Form 420 January 2021Common Stock · traded 15 January 2021 · filed 20 January 2021
- exercised options over 2,000 shares of Adaptive Biotechnologies (a derivative holding)SEC Form 420 January 2021Stock Option (Right to Buy) · traded 15 January 2021 · filed 20 January 2021
- exercised options over 1,500 shares of NanoString TechnologiesSEC Form 419 January 2021Common Stock · traded 15 January 2021 · filed 19 January 2021
- ▼ sold on the open market 709 shares of NanoString TechnologiesSEC Form 419 January 2021Common Stock · traded 15 January 2021 · filed 19 January 2021
- ▼ sold on the open market 410 shares of NanoString TechnologiesSEC Form 419 January 2021Common Stock · traded 15 January 2021 · filed 19 January 2021
- ▼ sold on the open market 291 shares of NanoString TechnologiesSEC Form 419 January 2021Common Stock · traded 15 January 2021 · filed 19 January 2021
- ▼ sold on the open market 90 shares of NanoString TechnologiesSEC Form 419 January 2021Common Stock · traded 15 January 2021 · filed 19 January 2021
- exercised options over 1,500 shares of NanoString Technologies (a derivative holding)SEC Form 419 January 2021Stock Option (right to buy) · traded 15 January 2021 · filed 19 January 2021
- exercised options over 2,000 shares of Adaptive Biotechnologies (a derivative holding)SEC Form 416 December 2020Stock Option (Right to Buy) · traded 15 December 2020 · filed 16 December 2020
- exercised options over 2,000 shares of Adaptive BiotechnologiesSEC Form 416 December 2020Common Stock · traded 15 December 2020 · filed 16 December 2020
- ▼ sold on the open market 1,759 shares of Adaptive BiotechnologiesSEC Form 416 December 2020Common Stock · traded 15 December 2020 · filed 16 December 2020
- ▼ sold on the open market 241 shares of Adaptive BiotechnologiesSEC Form 416 December 2020Common Stock · traded 15 December 2020 · filed 16 December 2020
- exercised options over 1,500 shares of NanoString Technologies (a derivative holding)SEC Form 416 December 2020Stock Option (right to buy) · traded 15 December 2020 · filed 16 December 2020
- exercised options over 1,500 shares of NanoString TechnologiesSEC Form 416 December 2020Common Stock · traded 15 December 2020 · filed 16 December 2020
- ▼ sold on the open market 688 shares of NanoString TechnologiesSEC Form 416 December 2020Common Stock · traded 15 December 2020 · filed 16 December 2020
- ▼ sold on the open market 812 shares of NanoString TechnologiesSEC Form 416 December 2020Common Stock · traded 15 December 2020 · filed 16 December 2020
- was granted 73,251 shares of Silverback Therapeutics (a derivative holding)SEC Form 47 December 2020Stock Option (right to buy) · traded 3 December 2020 · filed 7 December 2020
- exercised options over 2,000 shares of Adaptive Biotechnologies (a derivative holding)SEC Form 418 November 2020Stock Option (Right to Buy) · traded 16 November 2020 · filed 18 November 2020
- exercised options over 2,000 shares of Adaptive BiotechnologiesSEC Form 418 November 2020Common Stock · traded 16 November 2020 · filed 18 November 2020
- ▼ sold on the open market 1,777 shares of Adaptive BiotechnologiesSEC Form 418 November 2020Common Stock · traded 16 November 2020 · filed 18 November 2020
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.